Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
77,867.53
(
-1.52%
)
News Focus
News Focus
Post# of 257579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

pcrutch

Send PM Follow Ignore
Followers 68
Posts 2711
Boards Moderated 0
Alias Born 02/25/2010

pcrutch

Re: jq1234 post# 129173

Sunday, 10/23/2011 11:32:12 PM

Sunday, October 23, 2011 11:32:12 PM

Post# of 257579
Certainly raises some serious questions about how well they will be able to market the drug given the safety profile. Imagine they will have the same reimbursement issues that Gilenya has had.

Still looks like BG12 is in first place of the oral MS drugs in late-stage development. Safety profile looked great at ECTRIMS. waiting on CONFIRM results...
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today